We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Plasma Serglycin Levels Evaluated for Diabetic Retinopathy Diagnosis

By LabMedica International staff writers
Posted on 04 Jan 2021
Diabetic retinopathy (DR), a microvascular complication caused by chronic diabetes mellitus (DM), is a significant threat to vision in adults, which may even lead to blindness and retinal detachment. More...
The clinical symptoms of DR include fibrosis, capillary obstruction, neovascularization, and increased vascular permeability.

Serglycin (SRGN) is known as a hematopoietic cell granule proteoglycan, exerting its function in the formation of mast cell secretory granules and mediates the storage of various compounds in secretory vesicles. Studies have shown that SRGN is mainly expressed in normal hematopoietic cells, endothelial cells, uterine decidua, and embryonic stem cells.

Ophthalmologists at the Ningbo Eye Hospital (Ningbo, China) recruited,130 DR patients (64 proliferative diabetic retinopathy (PDR) patients and 66 non‐proliferative diabetic retinopathy (NPDR) patients, 55 type 2 diabetes mellitus (T2DM) patients, and 46 healthy controls, between December 2016 and March 2018.

The team measured the expressions of SRGN in plasma samples and cells were by qPCR analysis. Total RNA was extracted and then reverse‐transcribed into cDNA and amplified on an ABI PCR System (Applied Biosystems, Bedford, MA, USA). Total proteins were isolated from plasma samples and cells and the protein concentrations were determined by a Bicinchoninic Acid Protein method and separated by 10% SDS‐PAGE. The scientists also performed cell culture and transfection and CCK‐8 cell proliferation assays. Flow cytometric and cell apoptosis assay were also conducted using a FACS Vantage Flow Cytometer System (BD Biosciences, San Diego, CA, USA).

The investigators communicated that SRGN was dramatically upregulated in NPDR and PDR cases compared with healthy controls and T2DM patients; meanwhile, the expression of SRGN was further increased in the PDR group with regard to the NPDR group. Additionally, the ROC analysis demonstrated that SRGN could distinguish the DR cases from type 2 diabetes mellitus (T2DM) patients and healthy controls. In vitro high‐glucose treatment showed that the SRGN expressions were dramatically increased. The loss of SRGN could partially counteract the inhibition of human retinal endothelial cells (HREC) proliferation caused by high‐glucose stimulation. Meanwhile, SRGN knockdown could reverse the promotion of HREC apoptosis induced by high glucose as well.

The authors concluded that SRGN was significantly upregulated in the serum of DR patients, and after high‐glucose treatment, SRGN promoted the proliferation of human retinal pigment epithelial cells and inhibited the modulation of SRGN. At the same time, SRGN levels were able to screen DR patients from T2DM and healthy populations. The study was published on December 12, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Ningbo Eye Hospital
Applied Biosystems
BD Biosciences



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.